trending Market Intelligence /marketintelligence/en/news-insights/trending/Z2Z7YjLE34LkhJ9PL8bAaA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Gelesis secures $84M to commercialize weight management drug Plenity

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Gelesis secures $84M to commercialize weight management drug Plenity

Gelesis Inc. secured over $84 million by selling shares worth $63.4 million and receiving $21.2 million in grants and loans.

Private equity firm Vitruvian Partners LLP was the largest investor in the equity trade.

Gelesis intends to use the capital secured to commercialize its FDA-approved weight management drug Plenity, which works by absorbing water in the stomach and mixing it with food to make a meal feel more filling.

Gelesis has obtained nearly $100 million this year to support the U.S. launch of Plenity, the company said in a statement.